|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10583205||POLAREAN||Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices|| |
(11 years from now)
|US11052161||POLAREAN||Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices|| |
(12 years from now)
Xenoview is owned by Polarean.
Xenoview contains Xenon Xe-129 Hyperpolarized.
Xenoview has a total of 2 drug patents out of which 0 drug patents have expired.
Xenoview was authorised for market use on 23 December, 2022.
Xenoview is available in gas;inhalation dosage forms.
Drug patent challenges can be filed against Xenoview from 2026-12-23.
The generics of Xenoview are possible to be released after 29 December, 2035.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Dec 23, 2027|
NCE-1 date: 2026-12-23
Market Authorisation Date: 23 December, 2022
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic